After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the treatment of Alzheimer's disease.

The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...

The European Medicines Agency has rejected Lilly’s Alzheimer’s drug Kisunla for a license, saying its benefits don’t outweigh ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say it shouldn't be approved.

Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

NEW YORK CITY, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Shanghai, China & JERSEY CITY, N.J., United States: ...

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...